SEC Comment Letter 0000000000-24-002553 to TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc.
Date: March 7, 2024 · CIK: 0001783328 · Accession: 0000000000-24-002553
AI Filing Summary & Sentiment
File numbers found in text: 333-277699
Letter
United States securities and exchange commission logo March 7, 2024 Zoran Zdraveski Chief Legal and Strategy Officer TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 Re:TScan Therapeutics, Inc. Registration Statement on Form S-3 Filed March 6, 2024 File No. 333-277699 Dear Zoran Zdraveski: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mitchell S. Bloom
Show Raw Text
United States securities and exchange commission logo
March 7, 2024
Zoran Zdraveski
Chief Legal and Strategy Officer
TScan Therapeutics, Inc.
830 Winter Street
Waltham, Massachusetts 02451
Re:TScan Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 6, 2024
File No. 333-277699
Dear Zoran Zdraveski:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Mitchell S. Bloom